PoCP NPDR Study, 1 dose vs placebo, 12 wk
Research payments
$649,873
Through program year 2023, $649,873 in research payments was reported against PoCP NPDR Study, 1 dose vs placebo, 12 wk, across 32 payments, paid by Boehringer Ingelheim Pharmaceuticals, Inc..
- Paid by
- Boehringer Ingelheim Pharmaceuticals, Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $20,229 | 1 |
| 2022 | Research | $17,815 | 1 |
| 2021 | Research | $281 | 1 |
| 2020 | Research | $254,553 | 15 |
| 2019 | Research | $356,995 | 14 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
8 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Allen Hu Martinsburg, WV Named on 4 payments
- Amani Fawzi Chicago, IL Named on 4 payments
- Derek Kunimoto Phoenix, AZ Named on 4 payments
- Harsha Sen Dothan, AL Named on 4 payments
- Dilsher Dhoot Santa Barbara, CA Named on 3 payments
- Paul Hahn Teaneck, NJ Named on 3 payments
- Matthew Cunningham Clermont, FL Named on 2 payments
- David Rhee Great Neck, NY Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.